Transition Therapeutics, Canada

Last updated: 13.02.2014

tt-logo.gifTransition is a biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company’s lead drug candidates are ELND005 for Alzheimer’s disease and bipolar disorder, and TT401 for type 2 diabetes with accompanying obesity. The Company’s shares are listed on the NASDAQ (TTHI) and TSX (TTH).

101 College Street, Suite 220, Toronto, Ontario, Canada M5G 1L7
Tel: 416-260-7770



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here